CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 220 enrolled
Drug / intervention
trabectedindrug
Likely dose
Not stated in record
Key inclusion· 4
  • ✓Women aged ≥18 years
  • ✓Platinum-sensitive relapsed ovarian cancer
  • ✓Treatment with trabectedin + PLD according to local SmPC and reimbursement guidelines
  • ✓Prior exposure of at least 1 cycle of trabectedin + PLD and no more than 3 previous treatment lines
Key exclusion· 0

None specified.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02825420
NCT02825420N/ACompleted
CompareCT.gov

NonInterventional, Multicenter, Prospective, European Study to Describe the Effectiveness of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients According to SmPC Regardless of Previous Use of an Antiangiogenic Drug

PharmaMar·observational·Posted Jul 7, 2016·Updated Oct 29, 2021

In Brief

An observational study evaluating trabectedin for Relapsed Ovarian Cancer. Completed, enrolled 220 participants across 65 sites in 5 countries.

Detailed Summary

Non-interventional, multicenter, prospective, European study to describe the effectiveness of trabectedin + PLD in the treatment of relapsed ovarian cancer (ROC) patients according to SmPC regardless of previous use of an antiangiogenic drug

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed Ovarian Cancer
CountriesBelgium, France, Germany, Italy, Spain
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 7, 2016
Enrollment StartJul 28, 2015
Primary CompletionSep 18, 2019
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 10.0 years ago

Interventions

trabectedindrug